ExosomePlus was founded in 2018 to drive an extracellular vesicle (EV)
revolution, bringing the best EV isolation
and characterization platform in the field of
regenerative therapy to bear on research wide
challenges faced by pharmaceutics industry.

Moving discovery from the lab to the real world, ExosomePlus are forming strategic partnerships to help companies integrate high purity exosomes into targeting for greater efficacy, versatility, and results. Our decade of directed exosome and its application R&D before establishment have resulted in more than 10 patents and applications. With a majority of our professional staff and management, advisory board members having doctoral or other higher degrees, our employees bring extensive experience in our target markets. ExosomePlus draws on these human resources to serve the needs of industry leaders in  medical science with our core technology capabilities.